Weight & Body Composition
Body Composition During Menopause
Weight alone can miss menopause-related changes in fat distribution and lean mass. Waist, strength and clinical risk factors add useful context.
Many women say their body changed shape around menopause, even when their weight barely moved. Clothes fit differently around the middle. Humanic Blue follows that gap between the scale and what’s happening beneath it: research following women over time supports a change in average body composition, but it does not predict what will happen to every individual.
In the Study of Women’s Health Across the Nation (SWAN), body weight rose before the transition without accelerating at its start, while the rate of fat gain doubled and lean mass (nonfat tissue) began to decline around two years before the final menstrual period. In one SWAN site, average waist size grew by about 5.7 cm over six years. Weight and body mass index (BMI), a weight-for-height measure, therefore do not capture the whole pattern. The National Heart, Lung, and Blood Institute uses waist circumference alongside BMI and considers more than 35 inches unhealthy for nonpregnant women, while noting that risk interpretation can vary. Exercise trials support resistance training for lean tissue and aerobic or combined training for fat outcomes. Hormone therapy can affect body composition modestly, but body-shape change alone is not an established reason to start it.
Key Takeaways
- In SWAN, weight did not accelerate at the start of the transition, while average fat gain did and lean mass began to decline.
- These are population averages with substantial individual variation; menopause and chronological aging overlap.
- Waist circumference adds information about abdominal fat distribution that BMI alone can miss.
- Exercise has direct randomized-trial evidence for improving body-composition outcomes. Hormone-therapy effects are secondary and do not establish a body-composition indication.
What does the scale miss during menopause?
A 2021 clinical review concluded that aging and the menopause transition overlap: midlife weight gain is strongly age-related, while declining ovarian hormones are associated with redistribution toward abdominal fat, including visceral fat around internal organs. The review combines studies following women over time with research on biological processes; it does not isolate the effect of menopause in a randomized trial.
SWAN follows the changes over time. In a 2019 analysis using repeated DXA scans (X-ray estimates of body composition) tracked around the final menstrual period, weight rose linearly before menopause without speeding up when the transition began. The underlying composition did change, on average. The scale can therefore stay on its existing trajectory while fat and lean tissue follow different ones. This pattern and its limits are also covered in Protect Muscle During Menopause.
What actually shifts
SWAN’s larger analysis found the timing shift: average fat gain sped up and lean mass began declining at the start of the transition, with both slopes continuing until roughly two years after the final period. A smaller Michigan SWAN group supplied a useful reality check over six years: waist and fat mass rose while estimated skeletal muscle edged down. The exact averages are in Extra Insights, because they describe groups—not a forecast for one body.
The Michigan figures come from a 2007 analysis in the Journal of Clinical Endocrinology & Metabolism of about 540 women aged 42 to 52 at the start, measured yearly with bioelectrical impedance. The University of Michigan researchers concluded that both chronological aging and ovarian aging contributed to substantial changes in body composition. Rising follicle-stimulating hormone (FSH), a marker of ovarian aging, tracked with rising fat mass.
The Michigan figures describe one site, one measurement method and average change; they should not be used as an individual forecast. A separate SWAN analysis linked greater lean-mass loss during the transition with more later limb fractures, but that association was observational and does not show that changing body composition prevents fracture, as covered in the muscle article. Abdominal fat is covered in depth in Visceral Fat After Menopause.
How does the timing in SWAN help separate the menopause transition from aging more broadly?
How can body composition be measured?
Weight and BMI are useful screening measures, but they do not show where fat is stored or distinguish fat from lean tissue. The NHLBI explicitly describes BMI as a screening tool rather than a diagnosis of body fatness.
Waist circumference is a simple marker of abdominal fat distribution. The NHLBI associates a waist above 35 inches in nonpregnant women with higher heart-disease and type 2 diabetes risk. Its method places the tape around the middle just above the hip bones and records the measurement after breathing out. A threshold is a risk marker, not a diagnosis, and clinical interpretation may differ with ancestry, body size, pregnancy and health history.
DXA body composition scans estimate fat, lean soft tissue and bone mineral. SWAN used repeated DXA for its main analysis. Measurement error, device/software differences and hydration still matter, and a body-composition scan is not the same clinical question as an osteoporosis bone-density test. The method is covered in DEXA Scans Explained.
Bioelectrical impedance estimates fat and lean tissue from how the body resists a small electrical current. The Michigan SWAN site used this method under a research protocol; that does not validate every home scale or make small changes clinically meaningful.
Which differences between BMI, waist measurements and imaging matter when comparing findings?
What has changed body composition in trials?
Exercise. A 2023 meta-analysis included 101 randomized studies and about 5,700 postmenopausal women. Exercise increased several muscle or fat-free-mass measures and reduced fat mass, body-fat percentage, waist circumference and visceral fat. Aerobic and combined programs tended to perform better for fat outcomes; resistance and combined programs tended to perform better for muscle outcomes. The studies varied in program, duration, population and measurement method, so the review supports training categories rather than one exact prescription. The muscle evidence is covered in Protect Muscle During Menopause.
Hormone therapy. A 2022 meta-analysis of clinical trials of osteoporosis treatments in postmenopausal women found small improvements in lean mass and fat mass with hormone therapy versus placebo. It combined different treatment regimens and populations, and compared effects on body composition rather than clinical events such as fractures. The review also ranked treatments using direct and indirect comparisons across trials; those rankings do not establish that a treatment is appropriate for a particular person. A separate 2019 randomized-trial meta-analysis found no significant lean-mass preservation after a median two years.
These results do not establish body-shape change as a treatment use for hormone therapy. Its recognized symptom and bone uses, medical reasons to avoid it and individual risks are covered in Menopause and Longevity.
What’s Interesting
During menopause, the scale can give an incomplete impression. In SWAN, weight did not accelerate at the start of the transition, while fat gain doubled and lean mass began to fall on average. Waist, strength and clinical risk factors can therefore add information that weight alone cannot.
What This Means in Practice
The evidence here concerns fat distribution, lean tissue and risk markers, rather than extra years of life. For readers interested in living longer and better, these distinctions prevent a body-composition measurement from becoming a verdict on health.
- Waist measurements: When a clinician uses waist to follow risk, a consistent measurement method helps make results comparable.
- DXA and impedance: Both estimate body composition; small changes may reflect measurement variation.
- Exercise: The cited review found different patterns for resistance, aerobic and combined training. It did not establish one program for every woman.
- Hormone therapy: The reviews do not establish body-composition changes as a reason to begin treatment. Recognized uses and individual risks are separate questions.
- Cardiovascular and diabetes risk: NHLBI uses waist as one input. Blood pressure, blood fats, blood sugar, smoking and health history contribute other information.
A primary care clinician or menopause specialist can put these changes in context. A registered dietitian or trainer can help with nutrition and strength plans.
Bottom Line
Body composition can change around menopause even when the scale follows its previous trend. In SWAN, average fat gain accelerated and lean mass began declining around the start of the transition, while a single-site cohort recorded several centimeters of waist growth over six years. Waist and function add useful context; DXA and impedance remain estimates. Exercise has direct trial evidence for improving muscle- and fat-related outcomes. Hormone therapy may have small composition effects, but the reviews do not establish body-composition change as a treatment use. Whether modifying these patterns changes how long women live has not been established.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01Which part of the menopause conversation still feels most under-explained: muscle, bone, heart health, sleep, body composition, or symptoms?
- 02Where did this article help separate a normal transition from something worth bringing into care?
- 03What question would make a midlife health visit more specific without overgeneralizing from population evidence?
Extra Insights & Sources
The evidence summaries and linked sources behind this article. A cohort is a group followed over time. Lean mass includes muscle and other nonfat tissue; it is not a direct muscle measurement. Anthropometric measurements describe body size, such as waist circumference. Standardized effects put results from different measurement scales on a common statistical scale; they are not kilograms gained or lost. A nonsignificant result does not clearly establish a treatment difference.
What We Know
- Midlife weight and menopause-linked body-composition change overlap; SWAN did not find weight acceleration at transition onset. Supported.
- Average fat gain accelerated and lean mass declined around the transition in SWAN. Supported (longitudinal cohort; individual variation).
- Waist adds risk information that BMI alone may miss; NHLBI uses more than 35 inches as an unhealthy threshold for nonpregnant women. Established screening context, not a diagnosis.
- Exercise improves multiple body-composition outcomes in postmenopausal women. Supported (heterogeneous randomized trials).
- Hormone therapy may have small fat- and lean-mass effects, but it is not a body-composition treatment. Limited/secondary evidence.
What We Don’t Know
- Whether preventing these shifts during the transition lowers later heart disease or fractures. Unknown.
- Which women gain the most metabolic benefit from hormone therapy. Uncertain.
- Whether changing body composition in midlife extends lifespan. Unknown.
SWAN’s body-composition results
| Change | What SWAN found | Source |
|---|---|---|
| Fat mass | Rate of gain doubled at the start of the transition, continuing until about 2 years after the final period | Greendale et al., 2019 |
| Lean mass | Began declining at the start of the transition, over the same period | Greendale et al., 2019 |
| Fat mass (Michigan site) | +3.4 kg over 6 years | Sowers et al., 2007 |
| Skeletal muscle (Michigan site) | About −0.23 kg over 6 years | Sowers et al., 2007 |
| Waist (Michigan site) | About +5.7 cm over 6 years; slower after 1 year past the final period | Sowers et al., 2007 |
Source Materials
- Greendale et al., JCI Insight (2019), PMID 30843880 — Longitudinal SWAN analysis using repeated DXA measurements aligned to the final menstrual period. Supports the average fat-gain acceleration, lean-mass decline and nonaccelerating body-weight trajectory around transition onset. These are adjusted population trajectories, not individual forecasts.
- Sowers et al., Journal of Clinical Endocrinology & Metabolism (2007), PMID 17192296 — Six-year longitudinal analysis of 543 women aged 42–52 at the Michigan SWAN site using annual bioelectrical-impedance and anthropometric measurements. Supports the average 3.4-kg fat-mass increase, approximately 0.23-kg skeletal-muscle decrease and 5.7-cm waist increase. One site and impedance-derived compartments limit generalizability and precision.
- Ko and Kim, Obesity (2022), PMID 34932890 — Clinical narrative review synthesizing weight, body-composition, fat-distribution and cardiometabolic changes across the transition. Supports separating age-related midlife weight gain from menopause-associated fat redistribution; as a narrative review, it does not supply a single causal estimate.
- NHLBI, overweight and obesity diagnosis and healthy-weight guidance — Current federal sources for BMI as a screening tool, waist as a marker of abdominal fat distribution, the greater-than-35-inch threshold for nonpregnant women and the standardized measurement method. Thresholds support risk assessment, not diagnosis or a universal treatment decision.
- Khalafi et al., Experimental Gerontology (2023), PMID 37388207 — Meta-analysis of 101 randomized studies and 5,697 postmenopausal women. Supports exercise-related improvements in muscle/fat-free-mass measures, fat mass, body-fat percentage, waist and visceral fat, with outcome-specific patterns by training type. Considerable variation in programs, populations and measurement methods limits any single prescription.
- Zhang et al., anti-osteoporosis treatment and body composition meta-analysis (2022), PMID 36086691 — Clinical-trial meta-analysis reporting small standardized lean-mass and fat-mass effects with hormone therapy versus placebo. Varied interventions, surrogate outcomes and network rankings limit clinical interpretation; the review does not establish body-composition change as an indication for hormone therapy.
- Javed et al., JAMA Network Open (2019), PMID 31461147 — Meta-analysis of 12 randomized hormone-therapy trials, 4,474 women and median two-year follow-up. Found a nonsignificant 0.06-kg lean-mass difference and rated the evidence low certainty.
Related product and service comparisons
The companion comparison describes home electrical-impedance estimates and an in-person imaging service, including their different report formats.
Leave a Reply